Skip to content
Bull Bear Daily

Bull Bear Daily

Primary Menu
  • Home
  • Business
  • Domestic
  • Economy
  • Money
  • Politics
  • Top News
  • Newsletters
  • Home
  • 2024
  • June
  • 24
  • Wegovy-maker Novo Nordisk to spend $4.1 billion to boost US manufacturing
  • Business

Wegovy-maker Novo Nordisk to spend $4.1 billion to boost US manufacturing

Bull Bear Daily June 24, 2024

By Isabelle Yr Carlsson and Maggie Fick

COPENHAGEN/LONDON (Reuters) – Obesity drug-maker Novo Nordisk will spend $4.1 billion to build a U.S. facility to fill injection pens for its hugely popular weight-loss treatment Wegovy and diabetes drug Ozempic, it said on Monday.

Construction of the plant at Novo’s existing main U.S. manufacturing site in Clayton, North Carolina, will be completed between 2027 and 2029, and will add 1,000 workers to the 2,500 already employed there, the Danish company said. Novo opened the site 31 years ago.

Novo told Reuters late last year it was working to increase its in-house capacity to fill the injection pens – a process known as fill-finish – at some manufacturing sites in the U.S. and Europe.

Booming demand for Wegovy in the United States and the 10 other markets where it has so far been launched has propelled Novo’s shares to record highs and the company last year overtook LVMH to become Europe’s most valuable listed company.

But the success has left Novo facing shortages and forced to limit the number of patients taking the once-weekly injection.

Boosting output of Wegovy has become more urgent since rival Eli Lilly launched its own obesity drug Zepbound in the U.S. in December.

Neither company can produce enough to meet demand. Some experts predict that sales for obesity treatments could reach about $150 billion annually by the early 2030s.

Since launching Wegovy in the U.S. in mid-2021, Novo has spent billions to boost production – much of it at facilities in its native Denmark but also at other sites including the one in North Carolina.

In another attempt to grow Novo’s manufacturing capacity for Wegovy, Novo’s controlling shareholder Novo Holdings announced in February that it would buy Catalent, a large U.S.-based contract drugmaker that is a subcontractor for making Wegovy, for $16.5 billion.

Novo Holdings said that after the deal closes, it will sell three of Catalent’s fill-finish sites – in Italy, Belgium, and in the U.S. – onto Novo Nordisk.

Niels Laurbjerg Nielsen, a corporate vice president at Novo who is in charge of fill-finish manufacturing at the Clayton, North Carolina facility, said he could not comment on that deal.

In an interview with Reuters, he declined to specify how many more doses would be produced there once the new fill-finish factory opened, but said the investment was part of the company’s efforts to reach more patients.

The initial focus would be on producing Wegovy and Ozempic, although the manufacturing lines could produce other “future” medicines, he said, without specifying them.

(Reporting by Isabelle Yr Carlsson and Maggie Fick; editing by Barbara Lewis)

Continue Reading

Previous: Paramount Global to raise prices for its streaming plans
Next: AT&T wants Big Tech companies to pay into telecom, broadband subsidy fund

Related Stories

2025-07-07T113749Z_1_LYNXMPEL660DH_RTROPTP_4_DOW-SAUDI-LICENSE
  • Business

Dow to close three European chemical plants, cut 800 jobs

Bull Bear Daily July 7, 2025
2025-07-03T155111Z_1_LYNXMPEL620VU_RTROPTP_4_PRECIOUS-PLATINUM
  • Business

Analysis-Platinum prices have limited upside after June’s stellar rally

Bull Bear Daily July 3, 2025
2025-07-03T172246Z_1_LYNXMPEL6210M_RTROPTP_4_USA-SHALE-INDEPENDENTS
  • Business

US drillers cut oil and gas rigs for 10th week in a row, Baker Hughes says

Bull Bear Daily July 3, 2025

Live Market Pulse

The charting technology is provided by TradingView. Learn how to use theTradingView Stock Screener.

Recent Posts

  • Apple takes fight against $587 million EU antitrust fine to court
  • Tesla slides as Musk’s ‘America Party’ heightens investor worries
  • Apple takes fight against $587 million EU antitrust fine to court
  • Dow to close three European chemical plants, cut 800 jobs
  • Judge rules Abrego wrongful deportation challenge must proceed

You may have missed

  • Newsletters

Apple takes fight against $587 million EU antitrust fine to court

Bull Bear Daily July 7, 2025
2025-07-07T111428Z_3_LYNXMPEL6606P_RTROPTP_4_TESLA-RESULTS

Tesla slides as Musk’s ‘America Party’ heightens investor worries

Bull Bear Daily July 7, 2025
2025-07-07T091954Z_3_LYNXMPEL660AS_RTROPTP_4_APPLE

Apple takes fight against $587 million EU antitrust fine to court

Bull Bear Daily July 7, 2025
2025-07-07T113749Z_1_LYNXMPEL660DH_RTROPTP_4_DOW-SAUDI-LICENSE
  • Business

Dow to close three European chemical plants, cut 800 jobs

Bull Bear Daily July 7, 2025
  • Home
  • Privacy Policy
  • Terms of Service
  • Disclaimer
  • Contact Us
Copyright 2025 © All rights reserved | Bull Bear Daily | bullbeardaily.com